Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
A Transgenic Model of Visceral Obesity and the Metabolic Syndrome
Hiroaki Masuzaki,1Janice Paterson,23Hiroshi Shinyama,1Nicholas M. Morton,2John J. Mullins,3Jonathan R. Seckl,2Jeffrey S. Flier1*
The adverse metabolic consequences of obesity are best
predicted by the quantity of visceral fat. Excess glucocorticoids
producevisceral obesity and diabetes, but circulating glucocorticoidlevels are normal in typical obesity. Glucocorticoids can be producedlocally from inactive 11-keto forms through the enzyme 11
hydroxysteroiddehydrogenase type 1 (11 HSD-1). We created
transgenic mice overexpressing11 HSD-1 selectively in adipose
tissue to an extent similar tothat found in adipose tissue from obese
humans. These mice hadincreased adipose levels of corticosterone and
developed visceralobesity that was exaggerated by a high-fat diet. The
mice alsoexhibited pronounced insulin-resistant diabetes,
hyperlipidemia,and, surprisingly, hyperphagia despite hyperleptinemia.
Increasedadipocyte 11 HSD-1 activity may be a common molecular
etiologyfor visceral obesity and the metabolic syndrome.
1 Division of Endocrinology and Metabolism,
Department of Medicine, Beth Israel Deaconess Medical Center and
Harvard Medical School, 330 Brookline Avenue, Boston, MA, 02215, USA.
2 Endocrinology Unit, Molecular Medicine Center,
University of Edinburgh, Edinburgh, EH4 2XU, Scotland, UK.
3 Molecular Physiology Laboratory, University of
Edinburgh, Edinburgh, EH8 9AG, Scotland, UK.
*
To whom correspondence should be addressed. E-mail:
jflier{at}caregroup.harvard.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
NEWS OF THE WEEK
Trisha Gura (7 December 2001) Science294 (5549), 2071a.
[DOI: 10.1126/science.294.5549.2071a] |Summary »|Full Text »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.
Y. Liu, Y. Nakagawa, Y. Wang, L. Liu, H. Du, W. Wang, X. Ren, K. Lutfy, and T. C Friedman (2008)
J. Mol. Endocrinol.
41, 53-64
|Abstract »|Full Text »|PDF »
Insulin and Dexamethasone Dynamically Regulate Adipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1.
A. Balachandran, H. Guan, M. Sellan, S. van Uum, and K. Yang (2008)
Endocrinology
149, 4069-4079
|Abstract »|Full Text »|PDF »
Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor.
K. Yang, H. Guan, E. Arany, D. J. Hill, and X. Cao (2008)
FASEB J
22, 2452-2464
|Abstract »|Full Text »|PDF »
Sphingolipids, Insulin Resistance, and Metabolic Disease: New Insights from in Vivo Manipulation of Sphingolipid Metabolism.
Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome.
D. P Macfarlane, S. Forbes, and B. R Walker (2008)
J. Endocrinol.
197, 189-204
|Abstract »|Full Text »|PDF »
A novel selective 11{beta}-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis.
I J Bujalska, L L Gathercole, J W Tomlinson, C Darimont, J Ermolieff, A N Fanjul, P A Rejto, and P M Stewart (2008)
J. Endocrinol.
197, 297-307
|Abstract »|Full Text »|PDF »
Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue.
I. J. Bujalska, K. N. Hewitt, D. Hauton, G. G. Lavery, J. W. Tomlinson, E. A. Walker, and P. M. Stewart (2008)
Endocrinology
149, 2584-2591
|Abstract »|Full Text »|PDF »
Insulin regulation of MCP-1 in human adipose tissue of obese and lean women.
J. Westerbacka, A. Corner, M. Kolak, J. Makkonen, U. Turpeinen, A. Hamsten, R. M. Fisher, and H. Yki-Jarvinen (2008)
Am J Physiol Endocrinol Metab
294, E841-E845
|Abstract »|Full Text »|PDF »
Preadipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Is a Keto-Reductase and Contributes to Diet-Induced Visceral Obesity in Vivo.
R. A. De Sousa Peixoto, S. Turban, J. H. Battle, K. E. Chapman, J. R. Seckl, and N. M. Morton (2008)
Endocrinology
149, 1861-1868
|Abstract »|Full Text »|PDF »
Postnatal Programming of Glucocorticoid Metabolism in Rats Modulates High-Fat Diet-Induced Regulation of Visceral Adipose Tissue Glucocorticoid Exposure and Sensitivity and Adiponectin and Proinflammatory Adipokines Gene Expression in Adulthood.
S. Boullu-Ciocca, V. Achard, V. Tassistro, A. Dutour, and M. Grino (2008)
Diabetes
57, 669-677
|Abstract »|Full Text »|PDF »
Synergy Between Leptin Therapy and a Seemingly Negligible Amount of Voluntary Wheel Running Prevents Progression of Dietary Obesity in Leptin-Resistant Rats.
A. Shapiro, M. Matheny, Y. Zhang, N. Tumer, K.-Y. Cheng, E. Rogrigues, S. Zolotukhin, and P. J. Scarpace (2008)
Diabetes
57, 614-622
|Abstract »|Full Text »|PDF »
Suppression of 11{beta}-hydroxysteroid dehydrogenase type 1 with RNA interference substantially attenuates 3T3-L1 adipogenesis.
Y. Liu, F. Park, J. L. Pietrusz, G. Jia, R. J. Singh, B. C. Netzel, and M. Liang (2008)
Physiol Genomics
32, 343-351
|Abstract »|Full Text »|PDF »
Modulation of 11{beta}-Hydroxysteroid Dehydrogenase (11{beta}HSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11{beta}HSD1 Inhibitor.
R. Courtney, P. M. Stewart, M. Toh, M.-N. Ndongo, R. A. Calle, and B. Hirshberg (2008)
J. Clin. Endocrinol. Metab.
93, 550-556
|Abstract »|Full Text »|PDF »
Methionine restriction effects on 11 -HSD1 activity and lipogenic/lipolytic balance in F344 rat adipose tissue.
C. E. Perrone, D. A. L. Mattocks, G. Hristopoulos, J. D. Plummer, R. A. Krajcik, and N. Orentreich (2008)
J. Lipid Res.
49, 12-23
|Abstract »|Full Text »|PDF »
Demonstration of Proof of Mechanism and Pharmacokinetics and Pharmacodynamic Relationship with 4'-Cyano-biphenyl-4-sulfonic Acid (6-Amino-pyridin-2-yl)-amide (PF-915275), an Inhibitor of 11 -Hydroxysteroid Dehydrogenase Type 1, in Cynomolgus Monkeys.
B. G. Bhat, N. Hosea, A. Fanjul, J. Herrera, J. Chapman, F. Thalacker, P. M. Stewart, and P. A. Rejto (2008)
J. Pharmacol. Exp. Ther.
324, 299-305
|Abstract »|Full Text »|PDF »
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
A. M. Nuotio-Antar, D. L. Hachey, and A. H. Hasty (2007)
Am J Physiol Endocrinol Metab
293, E1517-E1528
|Abstract »|Full Text »|PDF »
Ceramide and Adenosine 5'-Monophosphate-Activated Protein Kinase Are Two Novel Regulators of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression and Activity in Cultured Preadipocytes.
N. Arai, H. Masuzaki, T. Tanaka, T. Ishii, S. Yasue, N. Kobayashi, T. Tomita, M. Noguchi, T. Kusakabe, J. Fujikura, et al. (2007)
Endocrinology
148, 5268-5277
|Abstract »|Full Text »|PDF »
Social stress and recovery: implications for body weight and body composition.
K. L. K. Tamashiro, M. M. N. Nguyen, M. M. Ostrander, S. R. Gardner, L. Y. Ma, S. C. Woods, and R. R. Sakai (2007)
Am J Physiol Regulatory Integrative Comp Physiol
293, R1864-R1874
|Abstract »|Full Text »|PDF »
11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.
M. Berthiaume, M. Laplante, W. T. Festuccia, K. Cianflone, L. P. Turcotte, D. R. Joanisse, G. Olivecrona, R. Thieringer, and Y. Deshaies (2007)
Am J Physiol Endocrinol Metab
293, E1045-E1052
|Abstract »|Full Text »|PDF »
Reduced 11{beta}-hydroxysteroid dehydrogenase type 1 activity in obese boys.
S. Wiegand, A. Richardt, T. Remer, S. A Wudy, J. W Tomlinson, B. Hughes, A. Gruters, P. M Stewart, C. J Strasburger, and M. Quinkler (2007)
Eur. J. Endocrinol.
157, 319-324
|Abstract »|Full Text »|PDF »
Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats.
G. Aslanidi, V. Kroutov, G. Philipsberg, K. Lamb, M. Campbell-Thompson, G. A. Walter, S. Kurenov, J. Ignacio Aguirre, P. Keller, K. Hankenson, et al. (2007)
Am J Physiol Endocrinol Metab
293, E726-E736
|Abstract »|Full Text »|PDF »
Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals.
Peripheral mechanisms contributing to the glucocorticoid hypersensitivity in proopiomelanocortin null mice treated with corticosterone.
Z. Michailidou, A. P Coll, C. J Kenyon, N. M Morton, S. O'Rahilly, J. R Seckl, and K. E Chapman (2007)
J. Endocrinol.
194, 161-170
|Abstract »|Full Text »|PDF »
Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain.
Hippocampal 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Messenger Ribonucleic Acid Expression Has a Diurnal Variability that Is Lost in the Obese Zucker Rat.
J. Buren, S.-A. Bergstrom, E. Loh, I. Soderstrom, T. Olsson, and C. Mattsson (2007)
Endocrinology
148, 2716-2722
|Abstract »|Full Text »|PDF »
Obstructive Sleep Apnea Syndrome Is Associated With Some Components of Metabolic Syndrome.
M. Kono, K. Tatsumi, T. Saibara, A. Nakamura, N. Tanabe, Y. Takiguchi, and T. Kuriyama (2007)
Chest
131, 1387-1392
|Abstract »|Full Text »|PDF »
Depot-Specific Modulation of Rat Intraabdominal Adipose Tissue Lipid Metabolism by Pharmacological Inhibition of 11{beta}-Hydroxysteroid Dehydrogenase Type 1.
M. Berthiaume, M. Laplante, W. Festuccia, Y. Gelinas, S. Poulin, J. Lalonde, D. R. Joanisse, R. Thieringer, and Y. Deshaies (2007)
Endocrinology
148, 2391-2397
|Abstract »|Full Text »|PDF »
The Glucose-6-Phosphate Transporter-Hexose-6-Phosphate Dehydrogenase-11{beta}-Hydroxysteroid Dehydrogenase Type 1 System of the Adipose Tissue.
P. Marcolongo, S. Piccirella, S. Senesi, L. Wunderlich, I. Gerin, J. Mandl, R. Fulceri, G. Banhegyi, and A. Benedetti (2007)
Endocrinology
148, 2487-2495
|Abstract »|Full Text »|PDF »
Differential Modulation of 3T3-L1 Adipogenesis Mediated by 11beta-Hydroxysteroid Dehydrogenase-1 Levels.
J. Kim, K. A. Temple, S. A. Jones, K. N. Meredith, J. L. Basko, and M. J. Brady (2007)
J. Biol. Chem.
282, 11038-11046
|Abstract »|Full Text »|PDF »
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
S. Nakano, Y. Inada, H. Masuzaki, T. Tanaka, S. Yasue, T. Ishii, N. Arai, K. Ebihara, K. Hosoda, K. Maruyama, et al. (2007)
Am J Physiol Endocrinol Metab
292, E1213-E1222
|Abstract »|Full Text »|PDF »
Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.
D. Qi and B. Rodrigues (2007)
Am J Physiol Endocrinol Metab
292, E654-E667
|Abstract »|Full Text »|PDF »
Increased 11beta-hydroxysteroid dehydrogenase type-1 and hexose-6-phosphate dehydrogenase in liver and adipose tissue of rat offspring exposed to alcohol in utero.
S. Nammi, K. Dembele, and B. L. G. Nyomba (2007)
Am J Physiol Regulatory Integrative Comp Physiol
292, R1101-R1109
|Abstract »|Full Text »|PDF »
Characterisation of 11{beta}-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat.
I. J Bujalska, O. M Durrani, J. Abbott, C. U Onyimba, P. Khosla, A. H Moosavi, T. T Q Reuser, P. M Stewart, J. W Tomlinson, E. A Walker, et al. (2007)
J. Endocrinol.
192, 279-288
|Abstract »|Full Text »|PDF »
Chemoprevention of rat prostate carcinogenesis by dietary 16{alpha}-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone.
D. L. McCormick, W. D. Johnson, N. M. Kozub, K.V.N. Rao, R. A. Lubet, V. E. Steele, and M. C. Bosland (2007)
Carcinogenesis
28, 398-403
|Abstract »|Full Text »|PDF »
Characterization of the transcriptional and functional effects of fibroblast growth factor-1 on human preadipocyte differentiation.
F. S. Newell, H. Su, H. Tornqvist, J. P. Whitehead, J. B. Prins, and L. J. Hutley (2006)
FASEB J
20, 2615-2617
|Abstract »|Full Text »|PDF »
PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.
S. Subramanian, M. A. DeRosa, C. Bernal-Mizrachi, N. Laffely, W. T. Cade, K. E. Yarasheski, P. E. Cryer, and C. F. Semenkovich (2006)
Am J Physiol Endocrinol Metab
291, E1365-E1371
|Abstract »|Full Text »|PDF »
Brain Adipocytokine Action and Metabolic Regulation.
R. S. Ahima, Y. Qi, N. S. Singhal, M. B. Jackson, and P. E. Scherer (2006)
Diabetes
55, S145-S154
|Abstract »|Full Text »|PDF »
Acute In Vivo Regulation of 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Activity by Insulin and Intralipid Infusions in Humans.
D. J. Wake, N. Z. M. Homer, R. Andrew, and B. R. Walker (2006)
J. Clin. Endocrinol. Metab.
91, 4682-4688
|Abstract »|Full Text »|PDF »
Splanchnic Cortisol Production in Dogs Occurs Primarily in the Liver: Evidence for Substantial Hepatic Specific 11{beta} Hydroxysteroid Dehydrogenase Type 1 Activity.
R. Basu, D. S. Edgerton, R. J. Singh, A. Cherrington, and R. A. Rizza (2006)
Diabetes
55, 3013-3019
|Abstract »|Full Text »|PDF »
Liver X Receptor Agonist T0901317 Inhibition of Glucocorticoid Receptor Expression in Hepatocytes May Contribute to the Amelioration of Diabetic Syndrome in db/db Mice.
Y. Liu, C. Yan, Y. Wang, Y. Nakagawa, N. Nerio, A. Anghel, K. Lutfy, and T. C. Friedman (2006)
Endocrinology
147, 5061-5068
|Abstract »|Full Text »|PDF »
Modulation of Early Human Preadipocyte Differentiation by Glucocorticoids.
J. J. Tomlinson, A. Boudreau, D. Wu, E. Atlas, and R. J. G. Hache (2006)
Endocrinology
147, 5284-5293
|Abstract »|Full Text »|PDF »
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity.
P. Darmon, F. Dadoun, S. Boullu-Ciocca, M. Grino, M.-C. Alessi, and A. Dutour (2006)
Am J Physiol Endocrinol Metab
291, E995-E1002
|Abstract »|Full Text »|PDF »
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences.
M.-C. Alessi and I. Juhan-Vague (2006)
Arterioscler. Thromb. Vasc. Biol.
26, 2200-2207
|Abstract »|Full Text »|PDF »
Adipose tissue 11{beta}-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome.
B. Mariniello, V. Ronconi, S. Rilli, P. Bernante, M. Boscaro, F. Mantero, and G. Giacchetti (2006)
Eur. J. Endocrinol.
155, 435-441
|Abstract »|Full Text »|PDF »
11{beta}-Hydroxysteroid Dehydrogenase Type 1 Induction in the Arcuate Nucleus by High-Fat Feeding: A Novel Constraint to Hyperphagia?.
V. S. Densmore, N. M. Morton, J. J. Mullins, and J. R. Seckl (2006)
Endocrinology
147, 4486-4495
|Abstract »|Full Text »|PDF »
Protein-mediated Fatty Acid uptake: novel insights from in vivo models..
Inhibiting Endogenous Cortisol Blunts the Meal-Entrained Rise in Serum Leptin.
B. Laferrere, C. Abraham, M. Awad, S. Jean-Baptiste, A. B. Hart, P. Garcia-Lorda, P. Kokkoris, and C. D. Russell (2006)
J. Clin. Endocrinol. Metab.
91, 2232-2238
|Abstract »|Full Text »|PDF »
Genetic Variation in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Predicts Adrenal Hyperandrogenism among Lean Women with Polycystic Ovary Syndrome.
A. Gambineri, V. Vicennati, S. Genghini, F. Tomassoni, U. Pagotto, R. Pasquali, and B. R. Walker (2006)
J. Clin. Endocrinol. Metab.
91, 2295-2302
|Abstract »|Full Text »|PDF »
A Novel Promoter for the 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Gene Is Active in Lung and Is C/EBP{alpha} Independent.
C. Bruley, V. Lyons, A. G. F. Worsley, M. D. Wilde, G. D. Darlington, N. M. Morton, J. R. Seckl, and K. E. Chapman (2006)
Endocrinology
147, 2879-2885
|Abstract »|Full Text »|PDF »
FATP1 Is an Insulin-Sensitive Fatty Acid Transporter Involved in Diet-Induced Obesity..
Q. Wu, A. M. Ortegon, B. Tsang, H. Doege, K. R. Feingold, and A. Stahl (2006)
Mol. Cell. Biol.
26, 3455-3467
|Abstract »|Full Text »|PDF »
Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11beta-HSD1 in the Syrian hamster.
A. E. Coutinho, J. E. Campbell, S. Fediuc, and M. C. Riddell (2006)
J Appl Physiol
100, 1483-1488
|Abstract »|Full Text »|PDF »
Complex Role of the Vitamin D Receptor and Its Ligand in Adipogenesis in 3T3-L1 Cells.
J. M. Blumberg, I. Tzameli, I. Astapova, F. S. Lam, J. S. Flier, and A. N. Hollenberg (2006)
J. Biol. Chem.
281, 11205-11213
|Abstract »|Full Text »|PDF »
G. G. Lavery, E. A. Walker, N. Draper, P. Jeyasuria, J. Marcos, C. H. L. Shackleton, K. L. Parker, P. C. White, and P. M. Stewart (2006)
J. Biol. Chem.
281, 6546-6551
|Abstract »|Full Text »|PDF »
Effect of Nutrient Ingestion on Total-Body and Splanchnic Cortisol Production in Humans.
R. Basu, R. Singh, A. Basu, C.M. Johnson, and R. A. Rizza (2006)
Diabetes
55, 667-674
|Abstract »|Full Text »|PDF »
Cortisol correlates with metabolic disturbances in a population study of type 2 diabetic patients.
K. M Oltmanns, B. Dodt, B. Schultes, H. H Raspe, U. Schweiger, J. Born, H. L Fehm, and A. Peters (2006)
Eur. J. Endocrinol.
154, 325-331
|Abstract »|Full Text »|PDF »
Obesity and the role of adipose tissue in inflammation and metabolism.
A. S Greenberg and M. S Obin (2006)
Am. J. Clinical Nutrition
83, 461S-465S
|Abstract »|Full Text »|PDF »
MCH-/- Mice Are Resistant to Aging-Associated Increases in Body Weight and Insulin Resistance.
J. Y. Jeon, R. L. Bradley, E. G. Kokkotou, F. E. Marino, X. Wang, P. Pissios, and E. Maratos-Flier (2006)
Diabetes
55, 428-434
|Abstract »|Full Text »|PDF »
Blood Glucose-Lowering Nuclear Receptor Agonists Only Partially Normalize Hepatic Gene Expression in db/db Mice.
M. Loffler, M. Bilban, M. Reimers, W. Waldhausl, and T. M. Stulnig (2006)
J. Pharmacol. Exp. Ther.
316, 797-804
|Abstract »|Full Text »|PDF »
Evidence That the 11 {beta}-Hydroxysteroid Dehydrogenase (11 {beta}-HSD1) Is Regulated by Pentose Pathway Flux: STUDIES IN RAT ADIPOCYTES AND MICROSOMES.
K. L. McCormick, X. Wang, and G. J. Mick (2006)
J. Biol. Chem.
281, 341-347
|Abstract »|Full Text »|PDF »
Meta-analysis of genome-wide linkage studies for quantitative lipid traits in African Americans.
A. Malhotra, H. Coon, M. F. Feitosa, W.-D. Li, K. E. North, R. A. Price, C. Bouchard, S. C. Hunt, J. K. Wolford, and The American Diabetes Association GENNID Study Gro (2005)
Hum. Mol. Genet.
14, 3955-3962
|Abstract »|Full Text »|PDF »
A Polygenic Model of the Metabolic Syndrome With Reduced Circulating and Intra-Adipose Glucocorticoid Action.
N. M. Morton, V. Densmore, M. Wamil, L. Ramage, K. Nichol, L. Bunger, J. R. Seckl, and C. J. Kenyon (2005)
Diabetes
54, 3371-3378
|Abstract »|Full Text »|PDF »
Differential effects of leptin administration on the abundance of UCP2 and glucocorticoid action during neonatal development.
M. G. Gnanalingham, A. Mostyn, R. Webb, D. H. Keisler, N. Raver, M. C. Alves-Guerra, C. Pecqueur, B. Miroux, M. E. Symonds, and T. Stephenson (2005)
Am J Physiol Endocrinol Metab
289, E1093-E1100
|Abstract »|Full Text »|PDF »
Adipokines: implications for female fertility and obesity.
M Mitchell, D T Armstrong, R L Robker, and R J Norman (2005)
Reproduction
130, 583-597
|Abstract »|Full Text »|PDF »
Prenatal nutritional programming of central obesity and the metabolic syndrome: role of adipose tissue glucocorticoid metabolism.
M. Grino (2005)
Am J Physiol Regulatory Integrative Comp Physiol
289, R1233-R1235
|Full Text »|PDF »
Ontogeny and nutritional programming of adiposity in sheep: potential role of glucocorticoid action and uncoupling protein-2.
M. G. Gnanalingham, A. Mostyn, M. E. Symonds, and T. Stephenson (2005)
Am J Physiol Regulatory Integrative Comp Physiol
289, R1407-R1415
|Abstract »|Full Text »|PDF »
Genetic manipulation of 11{beta}-hydroxysteroid dehydrogenases in mice.
J. M. Paterson, J. R. Seckl, and J. J. Mullins (2005)
Am J Physiol Regulatory Integrative Comp Physiol
289, R642-R652
|Abstract »|Full Text »|PDF »
11{beta}-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
A. Hermanowski-Vosatka, J. M. Balkovec, K. Cheng, H. Y. Chen, M. Hernandez, G. C. Koo, C. B. Le Grand, Z. Li, J. M. Metzger, S. S. Mundt, et al. (2005)
J. Exp. Med.
202, 517-527
|Abstract »|Full Text »|PDF »
Comparative enzymology of 11{beta}-hydroxysteroid dehydrogenase type 1 from six species.
S. Arampatzis, B. Kadereit, D. Schuster, Z. Balazs, R. A S Schweizer, F. J Frey, T. Langer, and A. Odermatt (2005)
J. Mol. Endocrinol.
35, 89-101
|Abstract »|Full Text »|PDF »
11{beta}-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes.
P. B. Jacobson, T. W. von Geldern, L. Ohman, M. Osterland, J. Wang, B. Zinker, D. Wilcox, P. T. Nguyen, A. Mika, S. Fung, et al. (2005)
J. Pharmacol. Exp. Ther.
314, 191-200
|Abstract »|Full Text »|PDF »
Obesity and Type 2 Diabetes Do Not Alter Splanchnic Cortisol Production in Humans.
R. Basu, R. J. Singh, A. Basu, E. G. Chittilapilly, M. C. Johnson, G. Toffolo, C. Cobelli, and R. A. Rizza (2005)
J. Clin. Endocrinol. Metab.
90, 3919-3926
|Abstract »|Full Text »|PDF »
hydroxysteroid dehydrogenase type 1 (11